Fig. 3

Immunogenicity test results for ra-βCs. A Cellular immunophenotypic test results; ****P < 0.0001 represents a very significant difference between aMSCs and ra-βCs. B Unidirectional mixed lymphocyte test results; **P < 0.01 indicates an extremely significant difference between PBMSCs (cocultured with aMSCs) and PBMSCs (cocultured with rRa -βCs), ^!!(P < 0.01) and ^!!!!(P < 0.0001) indicated that PBMSCs (co-culture with aMSCs) and PBMSCs (co-culture with ra-βCs) were significantly different from PBMSCs; ^####(P < 0.0001) represents a very significant difference between PBMSCs + PHA and other groups. C Results of lymphocytotoxicity test. ^##(P < 0.01) represents the extremely significant difference between aMSCs (co-culture with spleen cells presensitized by aMSCs) and ra-βCs (co-culture with spleen cells presensitized by ra-βCs), ****(P < 0.0001) showed extremely significant differences between aMSCs, ra-βCs and other groups. D Immunofluorescence detection results of GADA and ICA binding sites. E Peritoneal inflammatory infiltration test results, ****(P < 0.0001), ^####(P < 0.0001) and ^!!!!(P < 0.0001) represented extremely significant difference between intraperitoneal injection of aMSCs, intraperitoneal injection of ra-βCs and intraperitoneal injection of PBS, ^{^^^^}(P < 0.0001) represented an extremely significant difference between intraperitoneal injection of aMSCs and intraperitoneal injection of ra-βCs